智通财经网·2025-07-30 03:03Core Viewpoint - Fosun Pharma (02196) has seen a stock increase of over 4%, currently trading at HKD 20.15 with a transaction volume of HKD 201 million [1] Group 1: Licensing Agreement - Fosun Pharma's subsidiary has signed a licensing agreement with Newco, granting rights for the development, registration, production, and commercialization of AR1001 for Alzheimer's disease and other neurological disorders in designated regions (Mainland China and Hong Kong/Macau) [1] - Fosun Pharma will pay up to RMB 150 million to Newco for this licensing agreement [1] Group 2: Drug Development - The drug AR1001 was licensed from AriBioCO., Ltd. by Newco, which will continue its development [1] - Newco obtained exclusive rights for AR1001 in Greater China at the beginning of 2024 and is collaborating with AriBio to conduct global Phase III clinical trials targeting early Alzheimer's disease patients [1] - The global trial has completed recruitment in 13 countries and regions, including North America, Europe, the UK, China, and South Korea, with approximately 1,500 patients recruited worldwide [1]